Nasus Pharma Announces Transition of Chief Financial Officer
Rhea-AI Summary
Nasus Pharma (NYSE American: NSRX) announced that Chief Financial Officer Eyal Rubin will leave the company to pursue an opportunity outside the life science industry. Rubin will remain through September 18, 2026 to support a seamless and orderly transition.
Oren Elmaliach, currently Director of Finance, has been appointed Interim Chief Financial Officer. Elmaliach has been with Nasus since inception and is a certified public accountant with over 15 years of financial and life sciences experience, including work with US public markets and financial reporting. Nasus is a clinical-stage biopharmaceutical company developing intranasal therapies, led by product candidate NS002 for intranasal epinephrine in Type I allergic reactions, including anaphylaxis.
Positive
- Interim CFO appointed internally, Director of Finance Oren Elmaliach assumes role
- Interim CFO has 15+ years financial and leadership experience
- Elmaliach has been with Nasus since inception, supporting operational continuity
- Interim CFO has experience with US public markets and financial reporting
Negative
- Chief Financial Officer Eyal Rubin to leave Nasus on September 18, 2026
- CFO departure means near-term transition in company’s senior financial leadership
Market reaction after CFO leadership change: NSRX +5.21% in the Aug 19 session
In the Aug 19 session, NSRX gained 5.21%, reflecting a notable positive market reaction. Argus tracked a trough of -6.3% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. Trading volume was elevated at 2.2x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 17 | First-half earnings | Positive | +2.2% | Cash increased and Phase 2 data supported planned pivotal NS002 development. |
| Jul 28 | CEO appointment | Positive | -1.9% | Industry veteran Brendan O’Grady became CEO to advance NS002 and business development. |
| Jun 22 | Investor forum participation | Neutral | +1.6% | Nasus scheduled a virtual presentation and real-time question-and-answer session. |
| Jun 09 | NS003 preclinical results | Positive | -0.3% | Intranasal ondansetron showed comparable pharmacokinetics and favorable safety results. |
| Jun 01 | KOL event announcement | Neutral | -0.6% | Nasus scheduled a virtual event covering NS002 Phase 2 data and live Q&A. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Across five prior events, four price reactions diverged from the event tone, including declines after the CEO appointment and positive NS003 results.
Key Terms
intranasal medical
anaphylaxis medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE American: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that Chief Financial Officer, Eyal Rubin, will be leaving the Company to pursue a new opportunity outside of the life science industry. Mr. Rubin will remain with Nasus through September 18, 2026, and will work closely with the Company to ensure a seamless and orderly transition. Oren Elmaliach, the Company’s Director of Finance, has been appointed Interim Chief Financial Officer.
“I have known Eyal for over a decade and have always admired his contributions in any role,” said Brendan O’Grady, Chief Executive Officer of Nasus. “While I am disappointed that Eyal will be leaving Nasus, I am excited for him as he takes on a new challenge and opportunity. I appreciate his commitment to a seamless transition and look forward to working with him over the next several weeks. I also congratulate Oren Elmaliach as he assumes the role of Interim Chief Financial Officer. I have full confidence in Oren as he knows the Company exceptionally well and will provide important continuity as Nasus continues to move forward.”
“Eyal has made meaningful contributions to Nasus, playing an important role in our transition as a public company and in building the financial foundation for our next stage of development,” said Udi Gilboa, Chairman of the Board of Directors of Nasus Pharma. “We understand and fully support his decision to pursue this important next step in his career. On behalf of the Board and the entire Nasus team, I want to thank Eyal for his contributions, professionalism, and partnership and wish him every success in this next chapter.”
Mr. Elmaliach has been with Nasus since its inception and has extensive knowledge of the Company’s financial operations, reporting processes and organization.
A certified public accountant, Mr. Elmaliach brings more than 15 years of financial experience and leadership including significant experience supporting public and private life sciences companies and working within the US public markets and financial reporting environment.
About Nasus Pharma
Nasus Pharma Ltd. (NYSE American: NSRX) is a biopharmaceutical company advancing innovative intranasal therapies through its proprietary intranasal powder technology platform. The Company's lead product candidate, NS002, is being developed as an intranasal epinephrine treatment for Type I allergic reactions, including anaphylaxis. In addition to NS002, Nasus is leveraging its proprietary technology platform to develop a growing pipeline of differentiated intranasal product candidates designed to provide rapid, reliable and patient-friendly drug delivery across multiple therapeutic areas.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. Words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will”, “would,” or the negative of these words, similar expressions or variations of such words are intended to identify forward looking statements. For example, Nasus Pharma is using forward looking statements in this press release when it discusses: the timing of the chief financial officer role transition. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. These forward-looking statements are based on current expectations and and are subject to uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 25, 2026. Forward-looking statements contained in this press release are made as of this date, andhe Company undertakes no obligation to update or revise these forward-looking statements except as required by applicable law.
Company Contact
Nasus Pharma Ltd.
info@nasuspharma.com
Investor Contact
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
